NEW YORK (GenomeWeb News) – Epigenomics today announced an exclusive agreement with DPC Lebanon for the distribution of the Epi proColon colorectal cancer test in parts of the Middle East.
Under the agreement, DPC Lebanon will distribute the test for the early detection of colorectal cancer in blood in Lebanon, the United Arab Emirates, Saudi Arabia, Qatar, Kuwait, Syria, Jordan, and Egypt.
Financial terms were not disclosed.
Epigenomics last month inked a deal for distribution of the test in Israel with Pronto and in Turkey with Dateks. Today's deal "completes the picture for the Middle East," Geert Nygaard, CEO of Epigenomics, said in a statement. "DPC will join Dateks and Pronto as important partners in our continuously growing distributor network for our Epi proColon product."